“A phase 1 trial of the structure-based mRNA-1215 Nipah vaccine in healthy adults reported no serious adverse events and sustained antibody responses through one year.”

Checks out so far. 2 hold up so far.

0.7758 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.78, mostly supported · not yet reviewed by anyone else “A phase 1 trial of the structure-based mRNA-1215 Nipah vaccine in healthy adults reported no serious adverse events and sustained antibody responses through one year.” https://galedra.org/investigations/01a0eac0-23bb-7d3a-b6f6-b6912bde0c6b

“In a phase 1, first-in-human trial of mRNA-1215 in 40 healthy adults, no serious adverse events occurred during the study.”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card

“In the phase 1 mRNA-1215 trial, antibody responses increased after the booster dose and remained elevated for at least one year.”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card